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Oral Presentations 21develop symptom burden that substantially interferes with daily ac-
tivities. Acute graft-versus-host disease (aGVHD) may significantly
contribute to symptom burden.
Theoretical Framework: Symptom burden is the combined
impact of all symptoms on one’s ability to function as one did before
onset of disease and therapy.
Problem and Purpose: Symptom burden cannot be managed if it
is not reliably and sensitively measured over time. The purpose of
this study was to determine the reliability and sensitivity of the M.
D. Anderson Symptom Inventory (MDASI), a brief self-report
measure of the severity and impact of cancer-related symptoms, in
patients with and without aGVHD.
Methods: This is a retrospective analysis of a combined dataset of
125 patients who had completed multiple assessments using the
MDASIduring thefirst3months following alloHSCT.Symptombur-
denwasmeasuredusing the areaunder the curve (AUC)ofmeansymp-
tom severity scores from day of HSCT to 3 months after HSCT.
Results: Sample demographic, disease, and HSCT characteristics
andmean and standard deviations (SD) of symptom severity at 3 time
points are in shown Table 1. The MDASI symptom items had
a reliability index (Cronbach alpha) of 0.892. The MDASI symptom
items were sensitive enough to detect a significant difference in the
AUC of symptom severity from the day of HSCT to 3 months after
HSCT (p 5 0.025) and from 22 days to 3 months after HSCT (p 5
0.031) between patients with and without aGVHD.
Implications: The difference in symptom burden between
patients with and without aGVHD was not significant from the
day of HSCT to 22 days after HSCT.We had predicted that the dif-
ference would not be significant between the 2 groups during this
time period, as symptoms during this time are caused mainly by
the preparative regimen. We had predicted that the difference in
symptom severity would be greater between patients with and with-
out aGHVDbetween 22 and 100 days afterHSCT. ByDay 22, many
patients will have engrafted and aGVHD will begin to develop and
increase symptom burden. The MDASI is an easily-completed and
reliable measure of symptom burden in patients undergoing
alloHSCT and is sensitive enough to detect differences in symptom
burden between patients with and without aGVHD.
Table 1. Demographic/Treatment Characteristics and Symp-
tom Severity Means
N5125 N %Sex - Male 67 53.6%
Race - White, non-Hispanic 85 68.0%
Diagnosis
Acute leukemia/MDS 77 61.6%
Chronic leukemia 19 15.2%
Lymphoma 22 17.6%
Other 7 5.6%Type of HSCT
Related donor 94 75.2%





4 0 0Mean SD1Age 41.12 12.95
Highest Grade of
School Completed14.68 2.06No aGVHD aGVHD No aGVHD aGVHD
Mean Symptom
Severity Score - Day
of HSCT22.80 2.63 1.82 1.88Mean Symptom
Severity Score - Day 2222.21 2.66 1.78 1.87Mean Symptom
Severity Score - 3 Months21.43 2.36 1.35 1.791SD 5 standard deviation.
2Symptom severity: 0 to 10 scale, 05 not present 105 as bad as you can
imagine.LEUKEMIA
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The relatively higher risk of relapse after RIC allo-SCT, and con-
tinuous improvements in non-allo-SCT strategies, raise concern
about the utility of this approach in AML patients in CR1 (e.g. in
comparison to intensive chemotherapy and new drugs). Thus far,
no large studies have yet assessed the impact of cytogenetics risk on
outcome after RIC allo-SCT. This report describes the results of
378 AML patients transplanted in CR1 using a RIC regimen and re-
ported to the EBMT registry between 2000 and 2007, and for whom
detailed cytogenetics data were available. All patients received RIC
allo-SCTfromanHLA identical sibling.RICwasdefinedasBusulfan
conditioning regimens containing\ 8mg/kg total dose, or TBI\6
Gy: The median age was 55 (range, 18–74) y. The median intervals
from AML diagnosis to CR1 and from CR1 to RIC allo-SCT were
45 and 155 days respectively. In this series, 21 patients (6%) were in
the good cytogenetics risk group,while 304 patients (80%) and 53 pa-
tients (14%) belonged to the intermediate and poor cytogenetics risk
groups respectively. Age, year of transplant, WBC at diagnosis, gen-
der, CMV serostatus, stem cell source, and RIC regimen type were
comparable between all three groups. The M5-6-7 FAB subgroup
was significantly higher in the poor risk group (30% vs. 20% in the
intermediate group). With a median follow-up of 24 (range, 1–93)
months, the KM estimates of 2 years leukemia-free survival (LFS)
were 6464, 5763 and 3867% in the good-, intermediate-, and
poor-risk subgroups respectively (P 5 0.003). In multivariate analy-
sis, cytogenetics was not significantly associated with non-relapse
mortality. However, relapse incidence was significantly influenced
by the cytogenetics risk groups (P5 0.0001) and a higherWBCat di-
agnosis (P5 0.001). Finally, LFS was significantly influenced by the
cytogenetics risk groups (P5 0.004), a higherWBCat diagnosis (P5
0.006), and year of transplant (P 5 0.04). These results suggest that
RIC allo-SCT from anHLA-matched sibling donor is a valid option
for AMLpatients inCR1 not eligible for standard allo-SCT.As it has
been shown in the setting of myeloablative conditioning allo-SCT,
patients from the poor cytogenetics risk group had increased relapse
incidence and decreased LFS rate after RIC allo-SCT. Therefore,
prospective strategies such as use of new drugs, intensification of
conditioning regimen, post-transplant immunotherapy should be
investigate to improve current results in this group.51
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PBPC is an acceptable alternative to bone marrow (BM) for trans-
planting children with leukemia. Children and adolescents with leu-
kemia receiving PBSC compared to BM fromHLA-identical sibling
donors had more chronic graft-vs-host disease (GVHD), higher
transplant-relatedmortality (TRM) and lower leukemia-free survival
(LFS). We wanted to find out if children receiving unrelated donor
grafts should be given BM rather than PBPC. Therefore, we com-
pared the results of 385 unrelated donor BM transplants that were
allele-matched (n 5 186) or mismatched (n 5 199) at HLA A, B,
C, DRß1 and 110 PBPC transplants that were matched (n 5 60)
or mismatched (n 5 50) at HLA A, B, C, DRß1 in patients younger
